ABSTRACT
CHB
CHRONIC HEPATITIS, CHB
The authors declare a conflict of interest. Kelong Han, Robert Elston, Jennifer Cremer, Steve Hood, Melanie Paff, and Dickens Theodore are employees and stock/shareholders of GSK. Hiroshi Ito is an employee of GSK.GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants. In this analysis, the plasma pharmacokinetics (PK) of GSK3389404 were characterized and compared in patients with CHB across the Asia-Pacific region (N = 64), including mainland China (